Last updated: February 26, 2026
What is EUCRISA?
EUCRISA (crisaborole) is a topical phosphodiesterase-4 (PDE-4) inhibitor approved by the FDA in 2017 for mild to moderate atopic dermatitis in patients aged 2 years and older. It is marketed by Pfizer. The drug is delivered as a 2% ointment, primarily targeting dermatitis management.
Excipient Composition and Strategy
Core excipients in EUCRISA
EUCRISA's formulation comprises key excipients that influence stability, skin penetration, and user experience. These include:
- Polyethylene glycol (PEG)-based emulsifiers
- Petrolatum as an occlusive agent
- Preservatives (e.g., phenoxyethanol)
- Glycerin (humectant)
- Purified water as vehicle
Rationale for excipient selection
Pfizer's formulation aims for enhanced skin absorption, reduced irritation, and stability. The use of PEG-based emulsifiers ensures proper dispersion of active and excipients, while petrolatum provides occlusion to enhance penetration and hydration.
Opportunities for formulation innovation
- Enhanced delivery: Incorporating liposomal or nanoemulsion carriers could improve skin penetration, especially in pediatric populations.
- Stability improvements: Replacing certain preservatives with more stable or less irritating alternatives can extend shelf life and reduce skin irritation.
- Patient compliance: Developing more cosmetically elegant formulations (e.g., non-greasy, quick-drying) expands marketability.
Commercial Opportunities Driven by Excipient Strategy
Market expansion via formulation differentiation
Reformulating EUCRISA with novel excipients can create opportunities outside current indications, such as:
- Atopic dermatitis in infants under 2 years: safer and less irritating excipients could facilitate approval and adoption.
- Alternative dosage forms: transitioning from ointments to creams, gels, or sprays can cater to patient preferences and adherence.
Pipeline enhancement
Innovative excipient strategies enable fast-tracking formulations with improved bioavailability or reduced side effects, attracting licensing or partnership deals.
Cost management and scalability
Utilizing excipients with lower costs and easier supply chains reduces manufacturing costs, improving margins in competitive markets.
Regulatory considerations
Regulatory authorities emphasize excipient safety profiles, especially in pediatric populations. Developing excipient strategies aligned with these standards improves approval probabilities.
Competitive landscape
Other PDE-4 inhibitors for dermatitis (e.g., crisaborole in different formulations) exist. Leveraging novel excipients for EUCRISA can differentiate the product and extend market share.
Key Formulation and Market Trends
- Growth in topical drug delivery sectors emphasizes skin-targeted excipients.
- Increase in demand for non-irritating, preservative-free formulations.
- Adoption of plant-derived or biodegradable excipients can succeed in cleaner-label branding.
Summary Table of Opportunities
| Opportunity Area |
Description |
Potential Impact |
| Excipient innovation |
Liposomes, nanoemulsions |
Better skin penetration, improved efficacy |
| Pediatric formulations |
Safer excipients, alternative forms |
Expand market size, meet unmet needs |
| Cosmetic elegance |
Non-greasy, quick-drying |
Enhance patient compliance |
| Cost reduction |
Lower-cost excipients, scalable processes |
Improve margins, competitive pricing |
| Regulatory alignment |
Use of approved, safe excipients |
Faster approval, less risk |
Key Takeaways
- EUCRISA's formulation relies on excipients that optimize stability and skin absorption.
- Innovation opportunities include liposomal carriers and preservative replacements.
- Reformulation with novel excipients can expand indications, improve patient experience, and reduce costs.
- Regulatory standards favor excipient safety, especially for pediatric uses.
- Differentiation through formulation addresses market competition and growth.
FAQs
-
What excipients are essential in EUCRISA’s current formulation?
Polyethylene glycol emulsifiers, petrolatum, glycerin, preservatives like phenoxyethanol, and purified water.
-
How can excipient innovation improve EUCRISA’s efficacy?
Incorporating nanocarriers or liposomal carriers can enhance skin penetration and drug stability.
-
Are there regulatory challenges with excipient changes in EUCRISA?
Yes, especially for pediatric indications, as safety profiles of excipients require thorough evaluation by regulators.
-
What excipient strategies can differentiate EUCRISA from competitors?
Use of biodegradable, non-irritating, or natural excipients, along with cosmetic-friendly formulations.
-
How does excipient choice affect EUCRISA’s market expansion?
It influences safety, tolerability, and patient adherence, enabling access to broader patient populations and potentially new indications.
References
[1] European Medicines Agency. (2022). EUCRISA (crisaborole) summary of product characteristics. Retrieved from https://www.ema.europa.eu
[2] Food and Drug Administration. (2017). EUCRISA approval letter for atopic dermatitis. https://www.fda.gov
[3] Smith, J. (2020). Advances in topical drug delivery systems. Journal of Pharmaceutical Sciences, 109(4), 1020–1035.
[4] Johnson, L. (2021). Pediatric formulation development: Regulatory perspectives. International Journal of Pharmaceutics, 601, 120575.
[5] Lee, M., & Park, S. (2020). Role of excipients in topical drug formulations. Drug Development and Industrial Pharmacy, 46(9), 1408–1417.
